These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7824478)

  • 21. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
    Vick RN; Benevides M; Patel M; Parivar K; Linnet O; Carson CC
    J Urol; 2002 Jun; 167(6):2618-23. PubMed ID: 11992097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction.
    Porst H
    Int J Impot Res; 1997 Dec; 9(4):187-92. PubMed ID: 9442415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
    Loran OB; Segal AS; Shcheplev PA
    Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
    Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alprostadil sterile powder formulation for intracavernous treatment of erectile dysfunction.
    Colli E; Calabrò A; Gentile V; Mirone V; Soli M
    Eur Urol; 1996; 29(1):59-62. PubMed ID: 8821692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The use of PGE1 in the treatment of erectile deficiency].
    Arena F; Peracchia G; Di Stefano C; Cortellini P
    Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism.
    Schramek P; Dorninger R; Waldhauser M; Konecny P; Porpaczy P
    Br J Urol; 1990 Jan; 65(1):68-71. PubMed ID: 2310934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cavernous auto-injection therapy with prostaglandin E1.
    Nisén H
    Ann Chir Gynaecol Suppl; 1993; 206():69-73. PubMed ID: 8291874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
    Bratus D; Hlebic G; Hajdinjak T
    Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological erection program using prostaglandin E1.
    Gerber GS; Levine LA
    J Urol; 1991 Sep; 146(3):786-9. PubMed ID: 1875494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Initial experiences with prostaglandin E1 and PGE1 prepared injections].
    Mattarelli G; Leibundgut B
    Helv Chir Acta; 1991 Sep; 58(3):335-7. PubMed ID: 1769856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracavernous self-injection therapy for the treatment of erectile dysfunction.
    Chiang HS; Wen TC; Wu CC; Chiang WH
    J Formos Med Assoc; 1992 Sep; 91(9):898-901. PubMed ID: 1363391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Office treatment: intracavernous injections of prostaglandin E1 (PG E1) and improvement of spontaneous erections.
    Beretta G; Marzotto M; Zanollo A; Re B
    Acta Eur Fertil; 1991; 22(4):221-3. PubMed ID: 1844326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Our experience with pharmacological erection treatment of erectile dysfunction.
    Hattat H; Ozkara H; Akkus E; Alici B
    J Androl; 1994; 15 Suppl():47S-49S. PubMed ID: 7721677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections.
    Nandipati K; Raina R; Agarwal A; Zippe CD
    Int J Impot Res; 2006; 18(5):446-51. PubMed ID: 16482200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The patient's self-evaluation better predicts the degree of erectile dysfunction than the response to intracavernous alprostadil testing.
    Casella R; Deckart A; Bachmann A; Sulser T; Gasser TC; Lehmann K
    Urol Int; 2004; 72(3):216-20. PubMed ID: 15084765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction.
    Hirsch IH; Smith RL; Chancellor MB; Bagley DH; Carsello J; Staas WE
    Paraplegia; 1994 Oct; 32(10):661-4. PubMed ID: 7831071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.